Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.
| Property | Value |
|---|---|
| dbo:abstract |
|
| dbo:casNumber |
|
| dbo:chEMBL |
|
| dbo:fdaUniiCode |
|
| dbo:pubchem |
|
| dbo:thumbnail | |
| dbo:wikiPageID |
|
| dbo:wikiPageLength |
|
| dbo:wikiPageRevisionID |
|
| dbo:wikiPageWikiLink | |
| dbp:atcPrefix |
|
| dbp:c |
|
| dbp:casNumber |
|
| dbp:chembl |
|
| dbp:chemspiderid |
|
| dbp:f |
|
| dbp:h |
|
| dbp:iupacName |
|
| dbp:iupharLigand |
|
| dbp:legalStatus |
|
| dbp:n |
|
| dbp:o |
|
| dbp:pubchem |
|
| dbp:routesOfAdministration |
|
| dbp:smiles |
|
| dbp:stdinchi |
|
| dbp:stdinchikey |
|
| dbp:unii |
|
| dbp:width |
|
| dbp:wikiPageUsesTemplate | |
| dcterms:subject | |
| gold:hypernym | |
| rdf:type |
|
| rdfs:comment |
|
| rdfs:label |
|
| owl:sameAs | |
| prov:wasDerivedFrom | |
| foaf:depiction | |
| foaf:isPrimaryTopicOf | |
| is dbo:wikiPageWikiLink of | |
| is foaf:primaryTopic of |
